Zobrazeno 1 - 10
of 238
pro vyhledávání: '"E. Kaukel"'
Autor:
Ulrich Gatzemeier, Michael Boyer, Paolo Paoletti, Salih Emri, Christian Manegold, Claude Denham, Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Clet Niyikiza, E. Kaukel, Pierre Ruffié
Publikováno v:
Journal of Clinical Oncology. 41:2125-2133
PURPOSE Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase III trial to determine whether treatment with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::859d91608f4b04c049b1b2dc1a6776c2
https://doi.org/10.1200/jco.22.02542
https://doi.org/10.1200/jco.22.02542
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
P. Reiterer, J. von Pawel, N Iannotti, Isabel Bover, A. Riviere, Jack W. Singer, B. Bandstra, Philip Bonomi, Luis Paz-Ares, U. Gatzemeier, Mary O'Brien, Helen J. Ross, R García-Campelo, Lutz Freitag, Fred B. Oldham, W. Digel, E. Kaukel, Helge Bischoff, J Prendiville, Amy J. Eisenfeld
Publikováno v:
British Journal of Cancer
Paclitaxel poliglumex (PPX), a macromolecule drug conjugate linking paclitaxel to polyglutamic acid, reduces systemic exposure to peak concentrations of free paclitaxel. Patients with non-small-cell lung cancer (NSCLC) who had received one prior plat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49be46c74fd82ed4cd38ab0d41f59358
http://europepmc.org/articles/PMC2391114
http://europepmc.org/articles/PMC2391114
Autor:
Johan Vansteenkiste, Janusz Milanowski, Anna Pluzanska, Terezie Janaskova, Flavio De Rosa, Aleksandra Szczesna, Georgy M. Manikhas, E. Kaukel, Piotr Serwatowski, Rodryg Ramlau, Miloš Pešek, Jaromír Roubec, Ulrich Gatzemeier, Joachim von Pawel, Hanna Karnicka-Mlodkowski, János Strausz
Publikováno v:
Journal of Clinical Oncology. 25:1545-1552
Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase, with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of chemotherapy. This phase III, randomized, double-blind, place
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cce5b7afab9a77efddc233d733ae834b
https://doi.org/10.1200/jco.2005.05.1474
https://doi.org/10.1200/jco.2005.05.1474
Autor:
Frances A. Shepherd, Joachim von Pawel, Raymond P. Abratt, Kelly M. Grotzinger, Bernie Dharan, Graham Ross, Radj Gervais, E. Kaukel, Maciej Krzakowski, Rodryg Ramlau, Graham Dane
Publikováno v:
Journal of Clinical Oncology. 24:2800-2807
Purpose This open-label, randomized, multicenter, phase III study compared oral topotecan versus intravenous (IV) docetaxel in patients with previously treated non–small-cell lung cancer (NSCLC). Patients and Methods Patients with stage III or IV N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f457a057dfb9001496f60d5a300dbc0d
https://doi.org/10.1200/jco.2005.03.6491
https://doi.org/10.1200/jco.2005.03.6491
Autor:
Michael Millward, Chandra P. Belani, Anna Pluzanska, José Rodrigues Pereira, Vera Gorbounova, Frank V. Fossella, Aleksandra Szczesna, K. Mattson, E. Kaukel, Panagiotis Fidias, Joachim von Pawel, Rodryg Ramlau
Publikováno v:
Journal of Clinical Oncology. 21:3016-3024
Purpose: To investigate whether docetaxel plus platinum regimens improve survival and affect quality of life (QoL) in advanced non–small-cell lung cancer (NSCLC) compared with vinorelbine plus cisplatin as first-line chemotherapy. Patients and Meth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb2d3d8a4f78a8380c4c9ce543c6af68
https://doi.org/10.1200/jco.2003.12.046
https://doi.org/10.1200/jco.2003.12.046
Autor:
K. Dalhoff, U. Gatzemeier, E.-M. Ehlers, R Zumschlinge, S.O. Peters, G. J. Wiedemann, Th. Kohlmann, K. Eberhardt, S. Hegewisch-Becker, A Demedts, I. Bruns, Y Gruber, H.I Robins, E. Kaukel, G. Koschel, A. Bakhshandeh, Anne M. Traynor
Publikováno v:
Lung Cancer. 39:339-345
We performed a phase II study combining 41.8 degrees C whole body hyperthermia with ICE chemotherapy, i.e. ifosfamide (5 g/m(2)), carboplatin (300 mg/m(2)) and etoposide (150 mg/m(2) on days 2 and 3), administered every 4 weeks, for patients with mal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a93ea1e3ea439060ebd2dcec939fb7ca
https://doi.org/10.1016/s0169-5002(02)00536-6
https://doi.org/10.1016/s0169-5002(02)00536-6
Autor:
E. Kaukel, Sybill Hessler, Ulrich Gatzemeier, G. Koschel, Franziska Grunwald, Martin Reck, Joachim von Pawel, Urzula Jagos
Publikováno v:
Lung Cancer. 39:63-69
Purpose: We evaluated the toxicity and feasibility of adding paclitaxel to a standard platinum/etoposide regimen in the first-line treatment of patients with small cell lung cancer (SCLC). Patients and methods: Eighty-nine patients with limited disea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c03a088dc4c74f61671b7a7edc8988d
https://doi.org/10.1016/s0169-5002(02)00383-5
https://doi.org/10.1016/s0169-5002(02)00383-5